Related Experiment Video
Updated: Apr 9, 2026
Kinase Inhibitor Screening In Self-assembled Human Protein Microarrays
Published on: October 23, 2019
A pharmacological profile of pacritinib for the treatment of myelofibrosis
Hannah Goulart1, Lucia Masarova2, Naveen Pemmaraju2
1Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Introduction:
Myelofibrosis (MF) is a chronic myeloproliferative neoplasm characterized by splenomegaly, constitutional symptoms, progressive cytopenias, and limited overall survival. While Janus kinase (JAK) inhibitors have transformed symptom- and spleen-directed management, many patients, particularly those with baseline thrombocytopenia, historically had limited therapeutic options due to treatment-related myelosuppression and exclusion from pivotal trials. Pacritinib was developed to address this unmet need through selective JAK2, ACVR1, and IRAK1 inhibition with relative sparing of JAK1.
Areas Covered:
This review summarizes the pharmacologic properties, preclinical rationale, and clinical development of pacritinib for the treatment of MF. We discuss early-phase studies, pivotal phase III trials, dose-optimization efforts, and post-approval real-world data, with particular emphasis on patients with severe thrombocytopenia.
Expert Opinion:
Pacritinib occupies a distinct niche within the MF treatment landscape, offering meaningful spleen and symptom benefit in patients with severe thrombocytopenia who historically lacked effective therapeutic options. While no JAK inhibitor has demonstrated clear disease-modifying effects in MF, pacritinib's non-myelosuppressive profile, unique activity against IRAK1, and potential anemia benefit via ACVR1 inhibition suggests potential utility as a backbone for future combination strategies. Ongoing and future studies will be critical to further define its role in phenotype-driven MF management.
Insights
Pacritinib offers spleen and symptom relief for myelofibrosis patients with low platelets. This Janus kinase (JAK) inhibitor provides a non-myelosuppressive option, addressing a critical unmet need in treatment.
Area of Science:
- Hematology
- Oncology
- Pharmacology
Background:
- Myelofibrosis (MF) is a serious myeloproliferative neoplasm with significant morbidity.
- Current treatments, including JAK inhibitors, face challenges with myelosuppression, especially in patients with thrombocytopenia.
- Pacritinib was developed to target specific pathways while minimizing myelosuppression.
Purpose of the Study:
- To review the pharmacology, preclinical data, and clinical development of pacritinib for MF.
- To emphasize pacritinib's efficacy and safety in patients with severe thrombocytopenia.
- To discuss pacritinib's potential role in future combination therapies for MF.
Main Methods:
- Review of early-phase and pivotal Phase III clinical trials of pacritinib.
- Analysis of dose-optimization studies and real-world post-approval data.
- Focus on outcomes in patients with baseline severe thrombocytopenia.
Main Results:
- Pacritinib demonstrates significant spleen and symptom benefits in MF patients, including those with severe thrombocytopenia.
- The drug exhibits a favorable non-myelosuppressive profile compared to other JAK inhibitors.
- Potential benefits for anemia through ACVR1 inhibition were noted.
Conclusions:
- Pacritinib provides a valuable therapeutic option for MF patients with severe thrombocytopenia.
- Its unique inhibitory profile (JAK2, ACVR1, IRAK1) and non-myelosuppressive nature position it for potential combination strategies.
- Further research is needed to define pacritinib's optimal role in personalized MF management.
Related Concept Videos
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF